<<Agouron Pharmaceuticals, Inc. AGPH today announced fiscal 1998 net income of $13,154,000, or $.40 per share, on total revenues of $466,505,000. Fiscal 1998 sales of the company's anti-HIV drug VIRACEPT(R) (nelfinavir mesylate) were $409,298,000 which included sales in the United States of $358,321,000. Fourth quarter VIRACEPT sales in the United States were $105,633,000. Total VIRACEPT sales in the fourth quarter were $126,046,000, a 13% increase from the immediately preceding quarter. The fourth quarter net loss of $8,923,000, or $.29 per share, reflected the company's payment of licensing fees of $26,000,000 for three development-stage anti-HIV products. Prior to such license fees and related costs, fourth quarter and annual fiscal 1998 net income was $7,222,000 or $.22 per share and $29,659,000 or $.89 per share, respectively >>
This looks very good to me. |
